Baseline characteristics of patients enrolled in the study by endogenous EPO level
| . | Epoetin Alfa . | Placebo . | ||
|---|---|---|---|---|
| EPO ≤ 500 (N = 25) . | EPO > 500 (N = 20) . | EPO ≤ 500 (N = 12) . | EPO > 500 (N = 9) . | |
| % receiving RBC transfusion | 84.0 | 95.0 | 83.8 | 96.6 |
| % receiving platelet transfusion | 12.0 | 20.0 | 8.1 | 13.8 |
| Mean (±SD) units RBC transfused per patient during the 3 months before study | 7.75 (±9.69) | 13.31 (±8.73) | 9.01 (±6.87) | 12.96 (±9.09) |
| Total number of units RBC transfused during the 3 months before study | 163 | 253 | 90 | 117 |
| Mean hematocrit, % (±SD) | 27.7 (±4.7) | 25.6 (±4.11) | 27.98 (±5.08) | 25.58 (±4.29) |
| Mean ANC, cells/mL (±SD) | 948.4 (±945.1) | 899.5 (±476.7) | 819.2 (±420.0) | 1063.1 (±813.0) |
| . | Epoetin Alfa . | Placebo . | ||
|---|---|---|---|---|
| EPO ≤ 500 (N = 25) . | EPO > 500 (N = 20) . | EPO ≤ 500 (N = 12) . | EPO > 500 (N = 9) . | |
| % receiving RBC transfusion | 84.0 | 95.0 | 83.8 | 96.6 |
| % receiving platelet transfusion | 12.0 | 20.0 | 8.1 | 13.8 |
| Mean (±SD) units RBC transfused per patient during the 3 months before study | 7.75 (±9.69) | 13.31 (±8.73) | 9.01 (±6.87) | 12.96 (±9.09) |
| Total number of units RBC transfused during the 3 months before study | 163 | 253 | 90 | 117 |
| Mean hematocrit, % (±SD) | 27.7 (±4.7) | 25.6 (±4.11) | 27.98 (±5.08) | 25.58 (±4.29) |
| Mean ANC, cells/mL (±SD) | 948.4 (±945.1) | 899.5 (±476.7) | 819.2 (±420.0) | 1063.1 (±813.0) |
RBC, red blood cells; ANC, absolute neutrophil count; SD, standard deviation.